Health score, price, valuation, risk signals, and key metrics at a glance.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Grade capped at D — Interest coverage below 1× (-289.6x) — earnings cannot cover interest. Strongest: Balance Sheet & Red Flags (7/25); weakest: Cash & Earnings Quality (6/25).
Today's multiple positioned against its own trailing range — a visual premium/discount check.
Currently above its 16-quarter median.
Data-driven signals worth keeping an eye on across the last 8 quarters
The company posted negative operating margins in recent quarters — core operations are unprofitable.
Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.
as of June 2026
Revenue, EBITDA, operating income, net income, EPS, and shares
Gross, EBITDA, operating, and net margin trends
P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield
Total assets, cash, debt, book value, and leverage
Operating cash flow, free cash flow, FCF margin, and earnings quality
Currently near its 19-quarter median.
TTM revenue has contracted 96.6% — significant decline indicating deteriorating demand.
The last 8 consecutive quarters had negative FCF — the company is burning cash and may need external funding.
Shares outstanding increased 761.3% — significant dilution, likely from stock compensation or capital raises.
